Janssen Janina, Oevermann Anna, Walter Ingrid, Tichy Alexander, Kummer Stefan, Gradner Gabriele
Department of Small Animal Surgery, Ophthalmology, Dentistry and Physiotherapy, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
Division of Neurological Sciences, DCR-VPH, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland.
J Comp Pathol. 2023 Feb;201:41-48. doi: 10.1016/j.jcpa.2022.12.011. Epub 2023 Jan 25.
Osteopontin (OPN) is a matrix protein involved in tumour initiation and progression. In human meningioma, OPN has been correlated with World Health Organization (WHO) grade, brain invasion and recurrence. The aim of this study was to investigate OPN as a possible malignancy marker in canine meningioma by correlating its expression to WHO grade and proliferative activity as measured by the Ki-67 labelling index (LI). Thirty-five formalin-fixed, paraffin-embedded canine meningioma samples were classified according to the current human WHO classification. Evaluation of OPN expression was performed by immunohistochemical (IHC) labelling and calculation of the OPN intensity score (IS), OPN IHC score and Allred score. The scores were compared with WHO grades, Ki-67 LI, location and invasiveness. Nineteen meningiomas were graded as WHO grade I (54.3%), nine as grade II (25.7%) and seven as grade III (20.0%). Twenty-six tumours were located intracranially, four were retrobulbar and five were spinal meningiomas. In all specimens OPN expression was detected in moderate to high degrees. Neither the OPN scores nor the Ki-67 LIs were correlated with WHO grades. However, the OPN IS and OPN IHC score were significantly higher in WHO grade I samples compared with grade II samples (P <0.05). The OPN IS and OPN IHC score were significantly lower in meningioma samples that invaded surrounding tissues (P = 0.01 and 0.019, respectively). The results indicate a generally high expression of OPN in canine meningioma independent of WHO grade. Further research into the role of OPN as a possible therapeutic target or predictor of recurrence is warranted.
骨桥蛋白(OPN)是一种参与肿瘤起始和进展的基质蛋白。在人类脑膜瘤中,OPN与世界卫生组织(WHO)分级、脑侵袭和复发相关。本研究的目的是通过将OPN的表达与WHO分级以及通过Ki-67标记指数(LI)测量的增殖活性相关联,来研究OPN作为犬脑膜瘤可能的恶性标志物。根据当前人类WHO分类法对35个福尔马林固定、石蜡包埋的犬脑膜瘤样本进行分类。通过免疫组织化学(IHC)标记和计算OPN强度评分(IS)、OPN IHC评分和Allred评分来评估OPN表达。将这些评分与WHO分级、Ki-67 LI、位置和侵袭性进行比较。19个脑膜瘤被分级为WHO I级(54.3%),9个为II级(25.7%),7个为III级(20.0%)。26个肿瘤位于颅内,4个位于球后,5个为脊髓脑膜瘤。在所有标本中均检测到中度至高度的OPN表达。OPN评分和Ki-67 LI均与WHO分级无关。然而,与II级样本相比,WHO I级样本中的OPN IS和OPN IHC评分显著更高(P<0.05)。在侵袭周围组织的脑膜瘤样本中,OPN IS和OPN IHC评分显著更低(分别为P = 0.01和0.019)。结果表明,犬脑膜瘤中OPN的表达普遍较高,与WHO分级无关。有必要进一步研究OPN作为可能的治疗靶点或复发预测指标的作用。